Solid cyanine dyes
Polymorphs of Formula I, which is 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-phenoxycyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate and methods of making are provided. A method for organ imaging, comprising administering to a subject, a diagnostic effective amount of a composition comprising a polymorph of Formula I are also provided. In one embodiment, the organ includes one or more of kidney, bladder, ureter, urethra, bile ducts, liver, and gall bladder.
1. A solid polymorphic form of Formula I:
wherein the solid polymorphic form is a member selected from the group consisting of A-2, A-3, A-4, A-5, A-6, A-7, A-8, A-9, A-10, A-12 and A-13, wherein
Form A-2 is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 21.0201, 21.3092, 21.9298 and 16.4226 degrees 2θ (±0.2 degrees 2 θ);
Form A-3 is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 5.4582, 8.9758, 15.5042, 18.0678 degrees 2θ (±0.2 degrees 2 θ);
Form A-4 is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 4.6095, 6.1473, 11.9990, 12.4243, 16.4064, and 20.4115 degrees 2θ (±0.2 degrees 2 θ),
Form A-5 is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 5.0928, 5.3751, 7.1146, and 19.2858 degrees 2θ (±0.2 degrees 2 θ);
Form A-6 is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 11.8430, 4.7214, 5.6359, 10.7093, 17.1609 and 18.1502 degrees 2θ (±0.2 degrees 2 θ);
Form A-7 is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 21.1726, 21.0470, 11.9862, and 5.9858 degrees 2θ (±0.2 degrees 2 θ);
Form A-8 is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks 20.6831, 20.9865, and 19.0394 degrees 2θ (±0.2 degrees 2 θ);
Form A-9 is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks 20.6988, 15.2962, 13.9016, and 13.7110 degrees 2θ (±0.2 degrees 2 θ);
Form A-10 is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks 20.5520, 21.0470, 21.5370 and 19.0628 degrees 2θ (±0.2 degrees 2 θ);
Form A-12 is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks 21.0467, 20.5000 and 4.1778 degrees 2θ (±0.2 degrees 2 θ); and
Form A-13 is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks 20.8110, 11.9583 and 19.3205 degrees 2θ (±0.2 degrees 2 θ).
2. A method for kidney ureter imaging, the method comprising:
providing to a subject a composition comprising a diagnostic effective amount of a polymorph of Formula I according to claim 1 ;
administering said composition one or more times selected from the group consisting of before a procedure, during a procedure, after a procedure and combinations thereof,
exposing tissue of the subject's renal system to electromagnetic radiation; and
detecting fluorescence radiation from the compound.
3. The method of claim 2 , wherein the administering is conducted intravenously.
4. The method of claim 2 , wherein the pharmaceutically acceptable cation is selected from the group consisting of potassium or sodium.
5. The method of claim 2 , wherein the composition comprises a pharmaceutically acceptable carrier selected from the group consisting of physiological sterile saline solution, sterile water solution, pyrogen-free water solution, isotonic or 0.5N saline solution, and phosphate buffer solution.
6. The method of claim 2 , wherein the administering is conducted at a diagnostic effective amount of the compound ranging between approximately 0.01 μg/kg and approximately 3000.0 μg/kg.
7. The method of claim 2 , further comprising measuring a fluorescence intensity of the administered compound remaining at the tissue of the subject's renal system at a time period after administering.
8. The method of claim 2 , wherein the measured fluorescence intensity of the administered compound is comparable to background fluorescence approximately 24 hours after administering.
9. The method of claim 2 , wherein the procedure is selected from the group consisting of a laparoscopic procedure, a robotic procedure, a robotic laparoscopic procedure, and an open procedure.
10. The method of claim 7 , wherein the measured fluorescence intensity of the administered compound is higher in the kidney as compared to a measured fluorescence intensity of the administered compound in one or more of the spleen, intestine, heart, lungs, muscle, or combinations thereof approximately up to six hours after administering.
11. A pharmaceutical composition comprising a diagnostic imaging amount of a polymorph of Formula I,
wherein the polymorphic form is a member selected from the group consisting of A-2, A-3, A-4, A-5, A-6, A-7, A-8, A-9, A-10, A-12 and A-13, wherein
Form A-2 is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 21.0201, 21.3092, 21.9298 and 16.4226 degrees 2θ (±0.2 degrees 2 θ);
Form A-3 is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 5.4582, 8.9758, 15.5042, 18.0678 degrees 2θ (±0.2 degrees 2 θ);
Form A-4 is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 4.6095, 6.1473, 11.9990, 12.4243, 16.4064, and 20.4115 degrees 2θ (±0.2 degrees 2 θ),
Form A-5 is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 5.0928, 5.3751, 7.1146, and 19.2858 degrees 2θ (±0.2 degrees 2 θ);
Form A-6 is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 11.8430, 4.7214, 5.6359, 10.7093, 17.1609 and 18.1502 degrees 2θ (±0.2 degrees 2 θ);
Form A-7 is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 21.1726, 21.0470, 11.9862, and 5.9858 degrees 2θ (±0.2 degrees 2 θ);
Form A-8 is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks 20.6831, 20.9865, and 19.0394 degrees 2θ (±0.2 degrees 2 θ);
Form A-9 is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks 20.6988, 15.2962, 13.9016, and 13.7110 degrees 2θ (±0.2 degrees 2 θ);
Form A-10 is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks 20.5520, 21.0470, 21.5370 and 19.0628 degrees 2θ (±0.2 degrees 2 θ);
Form A-12 is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks 21.0467, 20.5000 and 4.1778 degrees 2θ (±0.2 degrees 2 θ);
Form A-13 is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks 20.8110, 11.9583 and 19.3205 degrees 2θ (±0.2 degrees 2 θ); and a pharmaceutically acceptable carrier.
12. The pharmaceutical composition of claim 11 , wherein the pharmaceutically acceptable carrier comprises saline.
13. The pharmaceutical composition of claim 11 , wherein the polymorph is a polymorph selected from the group consisting of A-2, A-3, and A-4.
14. The pharmaceutical composition of claim 11 , wherein the formulation comprises reconstitution of a lyophilized cake having a sugar or a sugar alcohol and an organic acid.
15. The pharmaceutical composition of claim 14 , wherein the acid is a member selected from the group consisting of citric acid, malic acid, tartaric acid, lactic acid, formic acid, ascorbic acid, fumaric acid, gluconic acid, succinic acid, maleic acid, adipic acid, and any mixture thereof.
16. The pharmaceutical composition of claim 14 , wherein the sugar or the sugar alcohol is a member selected from the group consisting of erythritol, tagatose, sucrose, fructose, glucose, sorbitol, mannitol, maltitol, xylitol, glycyrrhizin, malitol, maltose, lactose, xylose, arabinose, isomalt, lactitol, trehalulose, ribose, and any mixture thereof.
17. A kit comprising the pharmaceutical composition of claim 11 , and an instruction manual.